Does Johnson & Johnson Have Better Days Ahead for Its Device Biz?
Medical device sales continued to lag for Johnson & Johnson in the second quarter of 2015, though CEO Alex Gorsky sees plenty of future opportunities for the health product manufacturing giant.
The New Brunswick, NJ–based company saw medical device sales drop 12.2% year-over-year in the quarter to $6.4 billion, the company reported Tuesday. The decline follows last year’s $4 billion sale of J&J’s Ortho-Clinical Diagnostics (OCD) business to the Carlyle Group. OCD, which makes blood testing equipment, had generated annual sales of almost $2 billion.
Help employers find you! Check out all the jobs and post your resume.
The New Brunswick, NJ–based company saw medical device sales drop 12.2% year-over-year in the quarter to $6.4 billion, the company reported Tuesday. The decline follows last year’s $4 billion sale of J&J’s Ortho-Clinical Diagnostics (OCD) business to the Carlyle Group. OCD, which makes blood testing equipment, had generated annual sales of almost $2 billion.
Help employers find you! Check out all the jobs and post your resume.